Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose‐limiting toxicity (DLT) in colon can...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Ali, Raafi, Baracos, Vickie E., Sawyer, Michael B., Bianchi, Laurent, Roberts, Sarah, Assenat, Eric, Mollevi, Caroline, Senesse, Pierre
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4831278/
https://ncbi.nlm.nih.gov/pubmed/26814378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.621
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares